impf-info.de

Nachdem Covid19 aus medizinischer Sicht "durch" ist, hier jetzt also wieder das Thema Impfen in ganzer Breite...
Font size: +

Influenza - mRNA-Impfstoffe im Anflug

Einer Pressemitteilung von Moderna zu Folge hat der Influenza-mRNA-Impfstoff mRNA-1010 in einer Phase 3-Studie eine bessere Immunogenität erreicht, als vergleichbare konventionelle Influenza-Impfstoffe - dies lässt sich naturgemäß nicht überprüfen, da die Daten bislang nicht in einer Fachzeitschrift veröffentlicht wurden.

Beunruhigend sind jedoch die Aussagen zur Verträglichkeit: "...local and systemic solicited adverse reactions were similar to those reported in previous mRNA-1010 studies.". Diese Daten aus Phase 1/2-Studien wurden im Juni in Natur veröffentlicht und zeigten eine auffallend schlechte Verträglichkeit: je nach Altersgruppe mussten teilweise fast die Hälfte der Teilnehmer wegen Nebenwirkungen im Krankenhaus behandelt werden... (s. hier). 

Damals wie heute ist die Einstufung dieses katastrophal schlechten Sicherheitsprofils als "acceptable" entlarvend...

...

Moderna flu shot succeeds in late-stage study | Reuters

Moderna on Wednesday said its flu vaccine had generated a stronger immune response against all four A and B strains of the influenza virus compared to traditional flu shots in a late-stage trial.
...

Safety and immunogenicity of a phase 1/2 randomized clinical trial of a quadrivalent, mRNA-based seasonal influenza vaccine (mRNA-1010) in healthy adults: interim analysis | Nature Communications

Despite vaccine availability, influenza remains a substantial global public health concern. Here, we report interim findings on the primary and secondary objectives of the safety, reactogenicity, and humoral immunogenicity of a quadrivalent messenger RNA (mRNA) vaccine against seasonal influenza, mRNA-1010, from the first 2 parts of a 3-part, first-in-human, phase 1/2 clinical trial in healthy adults aged ≥18 years (NCT04956575). In the placebo-controlled Part 1, a single dose of mRNA-1010 (50 µg, 100 µg, or 200 µg) elicited hemagglutination inhibition (HAI) titers against vaccine-matched strains. In the active-comparator-controlled Part 2, mRNA-1010 (25 µg, 50 µg, or 100 µg) elicited higher HAI titers than a standard dose, inactivated seasonal influenza vaccine for influenza A strains and comparable HAI titers for influenza B strains. No safety concerns were identified; solicited adverse reactions were dose-dependent and more frequent after receipt of mRNA-1010 than the active comparator. These interim data support continued development of mRNA-1010. Here the authors report initial findings of a phase 1 clinical trial, showing that an investigational, mRNA-based vaccine for seasonal influenza (mRNA-1010) has no safety concerns and produces immune responses in adults that are similar or higher than a licensed comparator vaccine.
Polio - das Ziel der Ausrottung wird auch 2023 wei...
Covid PostVac - tragische Schicksale im Film

By accepting you will be accessing a service provided by a third-party external to https://impf-info.de/